GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.66
+9.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.84
From 52W high−57.88%
Volume1.90M
Market cap$909.44M
P/E (TTM)—
P/S (TTM)31.7x
Div yield—
Key dataOct 19, 2026
Open
$9.84
From 52W high
−57.88%
Volume
1.90M
Market cap
$909.44M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
39.8
MomentumView details →
1D Return
+9.45%
YTD Return
−33.08%
SummaryUpdated Jun 1, 2026
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. The company went public in June 2021 and specializes in developing innovative small molecule precision medicines that harness the body's natural protein degradation systems to treat cancer and immune-mediated diseases. Monte Rosa has emerged as a pioneer in the molecular glue degrader space, with multiple programs advancing through clinical development across oncology and immunology therapeutic areas.
Similar companies
Latest newsMore news →
Monte Rosa Therapeutics reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102 and outlined plans to advance the treatment into multiple Phase 2 studies.19d agoMonte Rosa Therapeutics reported its Q2 2026 financial results, with collaboration revenue of $9.0 million, a net loss of $43.4 million, and cash and investments of $626.0 million as of June 30, 2026.75d ago